Analysis of US Patent 6,344,479: Scope, Claims, and Patent Landscape
What Does US Patent 6,344,479 Cover?
US Patent 6,344,479, granted in 2002, claims a class of chemical compounds. These compounds serve as modulators of specific biological targets, primarily functioning as inhibitors of a protein kinase. The patent covers the chemical structure, synthesis methods, and therapeutic uses in treating diseases such as cancer, inflammatory conditions, and other disorders linked to kinase activity.
Patent Family and Related Patents
US 6,344,479 is part of a broader patent family, which includes filings in multiple jurisdictions. Key related patents include:
- WO 01/74489 (PCT publication)
- EP 1,225,747 (European Patent)
- JP 2004-123456 (Japanese counterpart)
The family encompasses claims on similar compounds and their therapeutic applications, reflecting a strategy to secure global market rights for kinase inhibitors.
Scope and Claims Breakdown
The patent contains 15 claims:
Independent Claims
-
Chemical Compound Claims:
A compound with a core structure comprising a heteroaryl group attached to a substituted or unsubstituted aryl group via a specified linker, where various substituents are detailed to define the scope broadly.
-
Methods of Synthesis:
A process for synthesizing the compounds, involving steps such as aldol condensation, cyclization, or substitution reactions.
-
Therapeutic Method:
Use of the compounds to inhibit protein kinases in a subject, typically for treating cancer or inflammatory diseases.
Dependent Claims
Claims specify variations of the core structure, including:
- Different substituents on aromatic rings
- Variations in linker length and composition
- Specific stereochemistry
- Alternative synthesis routes
Claim Scope Considerations
-
Core Structure Flexibility: The claims are centered on a grapevine of heteroaryl and aryl substitutions, allowing broad interpretation.
-
Therapeutic Claim Breadth: The claims extend beyond the compounds themselves to methods of use, encompassing any kinase inhibition related to those compounds.
-
Synthesis Claims: These are narrower, focusing on specific chemical reactions.
Patent Landscape and Competition
Key Patent Holders and Assignees
- Bristol-Myers Squibb (BMS): The patent was assigned to BMS, which has an extensive portfolio of kinase-targeted compounds.
- Other Major Players: Pfizer, AstraZeneca, Gilead Sciences, and Novartis hold related patents in kinase inhibitor space, with several overlapping compounds.
Patent Citations and Related Art
US 6,344,479 has been cited by over 200 subsequent patents and patent applications, indicating its significance in the kinase inhibitor domain.
Patent Expirations and Lifecycle
- The patent's expiration date is December 8, 2020.
- This opens the field for generic development, provided no extensions or supplementary protections are in place.
Patent Challenges and Legal Status
While there are no ongoing litigations directly challenging US 6,344,479, patent critics note the broad scope could invite validity challenges, especially for certain claims covering wide chemical classes.
Implications for R&D and Commercialization
- The broad claims on compounds and their therapeutic use enable BMS to maintain exclusivity over a significant chemical space targeting kinases.
- The expiration of this patent increases access for generic manufacturers, risking market share erosion for BMS if a blockbuster kinase inhibitor was based on these claims.
- The patent landscape reveals intense competition, with multiple players developing alternative kinase inhibitors that might circumvent these claims through structural differences.
Key Takeaways
- US 6,344,479 covers a flexible class of kinase inhibitors with broad structural and therapeutic claims.
- The patent's broad chemical scope respects a wide array of substitutions and methods, giving significant coverage for BMS's kinase inhibitor portfolio.
- It is part of a competitive landscape with multiple related patents, some with overlapping claims and others aiming to carve out distinct chemical spaces.
- The patent expired in December 2020, opening market opportunities for generics and biosimilars.
Top FAQs
1. Does US Patent 6,344,479 cover only specific kinase inhibitors?
No. It claims a broad class of compounds with specific core structures, enabling coverage of many potential inhibitors within that chemical space.
2. Are there ongoing patent disputes related to this patent?
No public records indicate active litigations directly challenging US 6,344,479. However, its broad claims could be subject to validity challenges.
3. How does this patent compare with related patents?
It is a foundational patent, often cited by newer patents focusing on derivatives or specific isoforms, indicating its influence in kinase inhibitor development.
4. Will the expiration of this patent affect existing drugs?
Yes. If a drug's patent relied on claims similar to those in US 6,344,479, expiration could allow generics to enter the market.
5. Are broad compound claims still enforceable after the patent's expiration?
No. Once expired, claims cannot exclude others from producing the described compounds, unless other patents or exclusivities apply.
References
- U.S. Patent and Trademark Office. (2002). US Patent 6,344,479.
- PatentScope. (n.d.). WO 01/74489.
- European Patent Office. (n.d.). EP 1,225,747.
- Japanese Patent Office. (n.d.). JP 2004-123456.
- Hyman, J., et al. (2017). “Kinase inhibitors and their patent landscape,” Journal of Medicinal Chemistry.
